What is Lifesci Capital's Forecast for LRMR Q2 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Research analysts at Lifesci Capital issued their Q2 2025 earnings per share estimates for shares of Larimar Therapeutics in a report issued on Monday, June 23rd. Lifesci Capital analyst C. Jubinville forecasts that the company will post earnings per share of ($0.46) for the quarter. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. Lifesci Capital also issued estimates for Larimar Therapeutics' Q3 2025 earnings at ($0.46) EPS and Q4 2025 earnings at ($0.46) EPS.

Several other equities research analysts have also weighed in on the company. Guggenheim reissued a "buy" rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a report on Tuesday. Wedbush cut their target price on Larimar Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday. Robert W. Baird cut their target price on Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday. Finally, HC Wainwright raised their target price on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, March 25th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $18.50.

Larimar Therapeutics Stock Down 1.6%

LRMR traded down $0.05 during trading hours on Wednesday, hitting $3.03. The stock had a trading volume of 1,913,731 shares, compared to its average volume of 851,133. The company's fifty day simple moving average is $2.41 and its 200 day simple moving average is $2.91. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $11.20. The stock has a market cap of $194.01 million, a PE ratio of -2.03 and a beta of 0.79.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Institutional Trading of Larimar Therapeutics

A number of large investors have recently modified their holdings of the business. Fi3 FINANCIAL ADVISORS LLC boosted its position in shares of Larimar Therapeutics by 16.7% during the 4th quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company's stock valued at $92,000 after acquiring an additional 3,411 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in Larimar Therapeutics by 12.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company's stock worth $137,000 after buying an additional 3,877 shares during the last quarter. Bank of America Corp DE lifted its position in Larimar Therapeutics by 8.1% in the 4th quarter. Bank of America Corp DE now owns 53,190 shares of the company's stock worth $206,000 after buying an additional 3,980 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in Larimar Therapeutics in the 4th quarter worth approximately $25,000. Finally, Wells Fargo & Company MN lifted its position in Larimar Therapeutics by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 19,657 shares of the company's stock worth $76,000 after buying an additional 6,701 shares during the last quarter. Institutional investors own 91.92% of the company's stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.